AIXC - Qualigen Therapeutics, Inc.

1.08
-0.045   -4.167%

Share volume: 46,413
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.31%

PREVIOUS CLOSE
CHG
CHG%
$1.12
-0.04
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
40%
Profitability 35%
Dept financing 43%
Liquidity 58%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.26%
1 Month
-23.94%
3 Months
-52.42%
6 Months
-37.57%
1 Year
-66.67%
2 Year
163.41%
Key data
Stock price
$1.08
P/E Ratio 
N/A
DAY RANGE
$1.06 - $1.18
EPS 
-$6.58
52 WEEK RANGE
$0.92 - $8.81
52 WEEK CHANGE
-$65.38
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
5.160 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
3.61
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$69,056
AVERAGE 30 VOLUME 
$79,396
Company detail
CEO: Michael S. Poirier
Region: US
Website: qualigeninc.com
Employees: 50
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Qualigen Therapeutics, Inc. develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers.

Recent news